105 related articles for article (PubMed ID: 15743206)
1. Discovery of a novel class of reversible non-peptide caspase inhibitors via a structure-based approach.
Fattorusso R; Jung D; Crowell KJ; Forino M; Pellecchia M
J Med Chem; 2005 Mar; 48(5):1649-56. PubMed ID: 15743206
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery of a novel non-peptidic small molecular inhibitor of caspase-3.
Sakai J; Yoshimori A; Nose Y; Mizoroki A; Okita N; Takasawa R; Tanuma S
Bioorg Med Chem; 2008 May; 16(9):4854-9. PubMed ID: 18387304
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10.
Ekici OD; Li ZZ; Campbell AJ; James KE; Asgian JL; Mikolajczyk J; Salvesen GS; Ganesan R; Jelakovic S; Grütter MG; Powers JC
J Med Chem; 2006 Sep; 49(19):5728-49. PubMed ID: 16970398
[TBL] [Abstract][Full Text] [Related]
4. A novel method for evaluation and screening of caspase inhibitory peptides by the amino acid positional fitness score.
Yoshimori A; Takasawa R; Tanuma S
BMC Pharmacol; 2004 May; 4():7. PubMed ID: 15154972
[TBL] [Abstract][Full Text] [Related]
5. N-benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: synthesis, in vitro activity, and molecular modeling studies.
Chu W; Zhang J; Zeng C; Rothfuss J; Tu Z; Chu Y; Reichert DE; Welch MJ; Mach RH
J Med Chem; 2005 Dec; 48(24):7637-47. PubMed ID: 16302804
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach.
Lakshmi PJ; Kumar BV; Nayana RS; Mohan MS; Bolligarla R; Das SK; Bhanu MU; Kondapi AK; Ravikumar M
Bioorg Med Chem; 2009 Aug; 17(16):6040-7. PubMed ID: 19631549
[TBL] [Abstract][Full Text] [Related]
7. Using peptidic inhibitors to systematically probe the S1' site of caspase-3 and caspase-7.
Goode DR; Sharma AK; Hergenrother PJ
Org Lett; 2005 Aug; 7(16):3529-32. PubMed ID: 16048334
[TBL] [Abstract][Full Text] [Related]
8. Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.
Han Y; Giroux A; Colucci J; Bayly CI; Mckay DJ; Roy S; Xanthoudakis S; Vaillancourt J; Rasper DM; Tam J; Tawa P; Nicholson DW; Zamboni RJ
Bioorg Med Chem Lett; 2005 Feb; 15(4):1173-80. PubMed ID: 15686936
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8.
James KE; Asgian JL; Li ZZ; Ekici OD; Rubin JR; Mikolajczyk J; Salvesen GS; Powers JC
J Med Chem; 2004 Mar; 47(6):1553-74. PubMed ID: 14998341
[TBL] [Abstract][Full Text] [Related]
10. Reducing the peptidyl features of caspase-3 inhibitors: a structural analysis.
Becker JW; Rotonda J; Soisson SM; Aspiotis R; Bayly C; Francoeur S; Gallant M; Garcia-Calvo M; Giroux A; Grimm E; Han Y; McKay D; Nicholson DW; Peterson E; Renaud J; Roy S; Thornberry N; Zamboni R
J Med Chem; 2004 May; 47(10):2466-74. PubMed ID: 15115390
[TBL] [Abstract][Full Text] [Related]
11. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
[TBL] [Abstract][Full Text] [Related]
12. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new inhibitors of D-alanine:D-alanine ligase by structure-based virtual screening.
Kovac A; Konc J; Vehar B; Bostock JM; Chopra I; Janezic D; Gobec S
J Med Chem; 2008 Dec; 51(23):7442-8. PubMed ID: 19053785
[TBL] [Abstract][Full Text] [Related]
14. Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity.
Pereira NA; Song Z
Biochem Biophys Res Commun; 2008 Dec; 377(3):873-7. PubMed ID: 18976637
[TBL] [Abstract][Full Text] [Related]
15. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
[TBL] [Abstract][Full Text] [Related]
16. In situ assembly of enzyme inhibitors using extended tethering.
Erlanson DA; Lam JW; Wiesmann C; Luong TN; Simmons RL; DeLano WL; Choong IC; Burdett MT; Flanagan WM; Lee D; Gordon EM; O'Brien T
Nat Biotechnol; 2003 Mar; 21(3):308-14. PubMed ID: 12563278
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
Medina-Franco JL; Giulianotti MA; Yu Y; Shen L; Yao L; Singh N
Bioorg Med Chem Lett; 2009 Aug; 19(16):4634-8. PubMed ID: 19604696
[TBL] [Abstract][Full Text] [Related]
18. Structure-based development of target-specific compound libraries.
Orry AJ; Abagyan RA; Cavasotto CN
Drug Discov Today; 2006 Mar; 11(5-6):261-6. PubMed ID: 16580603
[TBL] [Abstract][Full Text] [Related]
19. Identification of some novel AHAS inhibitors via molecular docking and virtual screening approach.
Wang JG; Xiao YJ; Li YH; Ma Y; Li ZM
Bioorg Med Chem; 2007 Jan; 15(1):374-80. PubMed ID: 17049866
[TBL] [Abstract][Full Text] [Related]
20. Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
Miguet L; Zervosen A; Gerards T; Pasha FA; Luxen A; Distèche-Nguyen M; Thomas A
J Med Chem; 2009 Oct; 52(19):5926-36. PubMed ID: 19746934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
